J&J Unit Revises Label For Evra Patch In Canada

Law360, New York (March 23, 2009, 12:00 AM EDT) -- Johnson & Johnson's Canadian subsidiary has updated labeling information for Evra, a birth control patch linked to blood clots, to state that the drug releases a greater amount of hormones on a daily basis than previously indicated.

Toronto-based Janssen-Ortho Inc. announced Thursday through Health Canada, the country's health care regulator, that it was changing the average daily release rates listed for the patch from 150 micrograms of norelgestromin, a progestin hormone, to 200 micrograms.

The figure listed for the amount of ethinyl estradiol, an estrogen hormone,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.